Radiopharmaceutical Manufacturing Unit

GSTT is seeking to commission an industry partner to design, build and operate a new, purpose-built Good Manufacturing Practice (GMP)-compliant Radiopharmaceutical Manufacturing Unit to support the growing demand for diagnostic (SPECT and PET) and therapeutic radiopharmaceuticals within close proximity of GSTT. It is anticipated a unit of 1,240 m2 within 1.5 miles of Guy’s Hospital will be leased by GSTT and discussions with the landlord are progressing. This initiative aims to establish a hub-and-spoke model, where the new unit will serve as the central hub, and the existing facility at Guy’s Hospital will continue as a spoke. This strategic development will:

• Increase manufacturing capacity for routine diagnostics and advanced clinical trials for GSTT and for the wider London market.
• Ensure equity of patient access to the latest RP diagnostics and therapeutics.
• Support innovative clinical research.
• Help future-proof Radiopharmacy services by adapting to evolving market demands.
• Develop the Radiopharmacy workforce through education and training programmes to ensure they are equipped with the skills and expertise needed to meet the evolving demands of the industry.

This initiative is part of GSTT’s strategic vision to lead in nuclear medicine, enhancing patient access to advanced diagnostics and therapies while driving innovation in radiopharmaceutical production. The new unit will also serve as a centre for education and training, developing the next generation of radiopharmacists and strengthening GSTT’s role as a leader in clinical research and healthcare excellence.

The Estimated Total Contract Value including VAT detailed below is illustrative and VAT will only be charged if applicable.